Summary of the effect on breastfeeding
AlemtuzumabLast Revision: June 21, 2021. Estimated reading time: 1 minute CASRN: 216503-57-0 Drug Levels and EffectsSummary of Use during LactationNo information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, alemtuzumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1-3] Drug LevelsMaternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date. Effects in Breastfed InfantsRelevant published information was not found as of the revision date. Effects on Lactation and BreastmilkRelevant published information was not found as of the revision date. Alternate Drugs to Consider(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta References
Substance IdentificationSubstance NameAlemtuzumab CAS Registry Number216503-57-0 Drug ClassBreast Feeding Antineoplastic Agents Antibodies, Monoclonal, Humanized Immunosuppressive Agents
|